Feasibility of an Oral Intervention for Sexual Health in Transgender Men

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

29 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-08-14

Study Completion Date

2024-11-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Transgender men (TGM) have a high incidence of sexually transmitted infected (STIs), including HIV, HPV and bacterial N. gonorrhea and C. trachomatis. In addition, TGM who start testosterone therapy (TT) experience significant vaginal morbidity that causes vaginal dryness and pain, due to the estrogen-inhibiting effects of TT on vaginal epithelium. Vaginal dysbiosis is a known contributor of increased STI risk and vaginal symptoms. In a future study, the investigators are planning a randomized trial of a 6-month oral Lactobacillus probiotics intervention in TGM on TT at the Callen-Lorde Community Health Center (CLCHC), New York City to determine whether this intervention can improve vaginal health in TGM on TT. In this study, the investigators will conduct a pilot and feasibility study to precede the main trial. The investigators will randomize 30 TGM on TT to receive either the intervention (consisting of Lactobacillus acidophilus GLA-14 and Lactobacillus rhamnosus HN001) or placebo (maltodextrin) for 4 weeks, evaluating the intervention's impact on vaginal microbiota and clinical outcomes, as well as its feasibility, acceptability, and adherence. This study will take place at the CLCHC Brooklyn site, aiming to gain pilot data, address feasibility and acceptability, and plan for the main trial accordingly.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Randomized Directly Observed Therapy Study to Interpret Clinical Trials of Doxy-PEP

NCT06414408

Sexually Transmitted Diseases, Bacterial

RECRUITING EARLY_PHASE1

Safety and Efficacy of Vaginal Microbiota Transplant (VMT) in Women With Bacterial Vaginosis (BV)

NCT03769688

Bacterial Vaginosis

WITHDRAWN PHASE1

Flourish Vaginal Care System to Establish Neovaginal Microbiome

NCT05372770

Neovaginal Microbiome

COMPLETED NA

Study Evaluating Conjugated Estrogen Cream for Atrophic Vaginitis

NCT00137371

Atrophic Vaginitis Atrophy Vaginitis

COMPLETED PHASE3

Interventional Study of Mucosal and Antimicrobial Responses to Repeated Vaginal Applications of Tenofovir Gel in HIV Uninfected Women

NCT00594373

HIV Infections

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Transgender men (TGM) have a higher risk of sexually transmitted infections (STIs) associated with vaginal dysbiosis, such as HIV, HPV and bacterial N. gonorrhea and C. trachomatis compared to cisgender women (CGW). TGM on testosterone therapy (TT) also have increased vaginal symptoms. Vaginal dysbiosis can be characterized as clinical-BV or molecular-BV (i.e. based on vaginal microbiota profile). Both are known contributors to increased vaginal symptoms and STI risk in CGW. Low Lactobacillus (LL) levels determine molecular-BV and clinical-BV. Studies show that TGM on TT show that they have a primarily LL vaginal microbiota. The investigators are planning a future study to test the efficacy of an oral Lactobacillus probiotic to improve vaginal health.

The goal for the future study is to test an intervention that the investigators hypothesize may be able to ameliorate some of the adverse health outcomes observed in TGM on TT. Thus, the investigators propose to use an intervention of a mixture of two components: 1) the probiotic Lactobacillus acidophilus GLA14 and 2) the probiotic Lactobacillus rhamnosus HN001. Studies have shown that an oral combination of this intervention increases vaginal Lactobacillus levels and improves vaginal health in CGW. The future study will test whether this intervention is effective in TGM on TT. This specific study is a pilot study to be conducted prior to the future study detailed above. Here, the investigators will randomize 30 TGM on TT to receive the intervention or placebo for 4 weeks. The intervention in the pilot study will be the same as the intervention of the main trial and will consist of the probiotics 1) Lactobacillus acidophilus GLA-14 and 2) Lactobacillus rhamnosus HN001. The placebo will be maltodextrin, the same as the proposed larger study. The investigators will assess the effect of the intervention on clinical-BV, molecular-BV (based on vaginal microbiota) and other clinical outcomes. Further, the investigators will determine the feasibility, acceptability, and adherence of the intervention. The investigators will conduct the pilot study at the CLCHC Brooklyn site. This pilot study will allow us to generate preliminary data, determine the feasibility and acceptability, and plan appropriately for the future study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vaginal Dysbiosis Vaginal Disease Molecular-bacterial Vaginosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

30 TGM on TT will be recruited and randomized them to take the intervention (n=15) or placebo (n=15).

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Phase 2 participants will be randomized at a 1:1 ratio (intervention: placebo) using a permuted block design. Concealment of random assignment will be accomplished by creation of randomized treatment assignment list, based on permuted block size, by a statistician/data manager at Columbia University who is not part of the investigative team. This statistician/data manager will hold the key to the treatment assignment and will also 1) communicate with the manufacturer on the labeling of sachets, 2) provide the random assignment list to the study site (which will lack information on treatment assignment or block size). In addition, the intervention and placebo will use identical packaging and labeling, and the placebo will have the same amount and similar taste/appearance as the intervention.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Probiotic Intervention

Participants will take one dose every day with water, for 4 weeks.

Group Type EXPERIMENTAL

Probiotic Group

Intervention Type DIETARY_SUPPLEMENT

The intervention is a mixture of two probiotics: 1) Lactobacillus acidophilus GLA-14 and 2) Lactobacillus rhamnosus HN001. These products will be combined into a single capsule/sachet with a dose of approximately 10\^10 colony forming units (CFUs) of GLA-14 (ATCC SD5212) and HN001 (ATCC SD5675) in a 4:1 ratio, using similar doses as recent studies using this product.

Placebo

Participants will take one dose every day with water, for 4 weeks.

Group Type PLACEBO_COMPARATOR

Placebo Group

Intervention Type DIETARY_SUPPLEMENT

The placebo will of be Maltodextrin, a carbohydrate, packaged similarly to the intervention and having the same weight.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Probiotic Group

The intervention is a mixture of two probiotics: 1) Lactobacillus acidophilus GLA-14 and 2) Lactobacillus rhamnosus HN001. These products will be combined into a single capsule/sachet with a dose of approximately 10\^10 colony forming units (CFUs) of GLA-14 (ATCC SD5212) and HN001 (ATCC SD5675) in a 4:1 ratio, using similar doses as recent studies using this product.

Intervention Type DIETARY_SUPPLEMENT

Placebo Group

The placebo will of be Maltodextrin, a carbohydrate, packaged similarly to the intervention and having the same weight.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 18-45 years
* Pre-menopausal
* Assigned female at birth and self-identity as TGM, male, transmasculine or nonbinary
* Presence of vagina and ovaries
* Currently on TT
* Stated willingness to join a randomized trial study, follow procedures, and answer questions about personal medical and sexual history

Exclusion Criteria

* Gender-affirming genital surgery (including phalloplasty, metoidioplasty, vaginectomy, hysterectomy, oophorectomy),
* Known allergic reactions to components of the intervention or placebo
* Have known HIV infection or symptomatic gonorrhea or chlamydia
* Are pregnant or planning to be pregnant during the study period
* Are on puberty-blockers
* Are currently taking or plan to take any non-study probiotics or any intravaginal product that may impact the outcomes of interest
* Use immunomodulatory or immunosuppressive drugs or are currently taking antibiotics or antifungals for \>14 days
* Have a severe illness (e.g., cancer, major psychiatric or neurological conditions), are planning to move away from the area during the study period, or have any condition that would make participation in the study unsafe (in the opinion of study staff)
* Have any condition that would make participation in the study unsafe (in the opinion of study staff), complicate interpretation of study outcome data, or otherwise interfere with achieving the study aims.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes